{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T04:58:37Z","timestamp":1764305917742},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00108-021-01233-4","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T18:09:26Z","timestamp":1641406166000},"page":"118-128","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antivirale Medikamente"],"prefix":"10.1007","volume":"63","author":[{"given":"Jakob J.","family":"Malin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Bunse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph D.","family":"Spinner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Protzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"1233_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00485-0","author":"F Ader","year":"2021","unstructured":"Ader\u00a0F, Bouscambert-Duchamp\u00a0M, Hites\u00a0M, Peiffer-Smadja\u00a0N, Poissy\u00a0J, Belhadi\u00a0D, Diallo\u00a0A, L\u00ea\u00a0M-P, Peytavin\u00a0G, Staub\u00a0T, Greil\u00a0R, Guedj\u00a0J, Paiva\u00a0J-A, Costagliola\u00a0D, Yazdanpanah\u00a0Y, Burdet\u00a0C, Mentr\u00e9\u00a0F, Egle\u00a0A, Greil\u00a0R, Joannidis\u00a0M, Lamprecht\u00a0B, Altdorfer\u00a0A, Belkhir\u00a0L, Fraipont\u00a0V, Hites\u00a0M, Verschelden\u00a0G, Aboab\u00a0J, Ader\u00a0F, Ait-Oufella\u00a0H, Andrejak\u00a0C, Andreu\u00a0P, Argaud\u00a0L, Bani-Sadr\u00a0F, Benezit\u00a0F, Blot\u00a0M, Botelho-Nevers\u00a0E, Bouadma\u00a0L, Bouchaud\u00a0O, Bougon\u00a0D, Bouiller\u00a0K, Bounes-Vardon\u00a0F, Boutoille\u00a0D, Boyer\u00a0A, Bruel\u00a0D, Cabi\u00e9\u00a0A, Canet\u00a0E, Cazanave\u00a0C, Chabartier\u00a0C, Chirouze\u00a0C, Clere-Jehl\u00a0R, Courjon\u00a0J, Crockett\u00a0F, Danion\u00a0F, Delbove\u00a0A, Dellamonica\u00a0J, Djossou\u00a0F, Dubost\u00a0C, Duvignaud\u00a0A, Epaulard\u00a0O, Epelboin\u00a0L, Fartoukh\u00a0M, Faure\u00a0K, Faure\u00a0E, Ferry\u00a0T, Ficko\u00a0C, Figueiredo\u00a0S, Gaborit\u00a0B, Gaci\u00a0R, Gagneux-Brunon\u00a0A, Gallien\u00a0S, Garot\u00a0D, Geri\u00a0G, Gibot\u00a0S, Goehringer\u00a0F, Gousseff\u00a0M, Gruson\u00a0D, Hansmann\u00a0Y, Hinschberger\u00a0O, Jaureguiberry\u00a0S, Jeanmichel\u00a0V, Kerneis\u00a0S, Kimmoun\u00a0A, Klouche\u00a0K, Lach\u00e2tre\u00a0M, Lacombe\u00a0K, Laine\u00a0F, Lanoix\u00a0J-P, Launay\u00a0O, Laviolle\u00a0B, Le Moing\u00a0V, Le Pavec\u00a0J, Le Tulzo\u00a0Y, Le Turnier\u00a0P, Lebeaux\u00a0D, Lefevre\u00a0B, Leroy\u00a0S, Lescure\u00a0F-X, Lessire\u00a0H, Leveau\u00a0B, Loubet\u00a0P, Makinson\u00a0A, Malvy\u00a0D, Marquette\u00a0C-H, Martin-Blondel\u00a0G, Martinot\u00a0M, Mayaux\u00a0J, Mekontso-Dessap\u00a0A, Meziani\u00a0F, Mira\u00a0J-P, Molina\u00a0J-M, Monnet\u00a0X, Mootien\u00a0J, Mourvillier\u00a0B, Murris-Espin\u00a0M, Navellou\u00a0J-C, Nseir\u00a0S, Oulehri\u00a0W, Peiffer-Smadja\u00a0N, Perpoint\u00a0T, Pialoux\u00a0G, Pilmis\u00a0B, Piriou\u00a0V, Piroth\u00a0L, Poissy\u00a0J, Pourcher\u00a0V, Quenot\u00a0J-P, Raffi\u00a0F, Reignier\u00a0J, Revest\u00a0M, Richard\u00a0J-C, B\u00e9atrice, C\u00e9line\u00a0R-P, Roger\u00a0RP-A, Roger\u00a0C, Rouveix-Nordon\u00a0E, Ruch\u00a0Y, Saidani\u00a0N, Sayre\u00a0N, Senneville\u00a0E, Sotto\u00a0A, Stefan\u00a0F, Tacquard\u00a0C, Terzi\u00a0N, Textoris\u00a0J, Thiery\u00a0G, Timsit\u00a0J-F, Tolsma\u00a0V, Turmel\u00a0J-M, Valour\u00a0F, Wallet\u00a0F, Wattecamps\u00a0G, Yazdanpanah\u00a0Y, Zerbib\u00a0Y, Berna\u00a0M, Reuter\u00a0J, Staub\u00a0T, Braz\u00a0S, Ferreira\u00a0J-M, Paiva\u00a0RJ-A, Roncon-Albuquerque\u00a0R, Bouscambert-Duchamp\u00a0M, Gaymard\u00a0A, L\u00ea\u00a0M-P, Lina\u00a0B, Peytavin\u00a0G, Tubiana\u00a0S, Couffin-Cadi\u00e8rgues\u00a0S, Esperou\u00a0H, Belhadi\u00a0D, Burdet\u00a0C, Costagliola\u00a0D, Dechanet\u00a0A, Delmas\u00a0C, Diallo\u00a0A, Fougerou\u00a0C, Guedj\u00a0J, Mentr\u00e9\u00a0F, Mercier\u00a0N, Noret\u00a0M, Saillard\u00a0J, Velou\u00a0P (2021) Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a\u00a0phase\u00a03 randomised controlled open-label trial. The Lancet Infectious Diseases. https:\/\/doi.org\/10.1016\/S1473-3099(21)00485-0","journal-title":"The Lancet Infectious Diseases"},{"key":"1233_CR2","unstructured":"Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF) (2018) Deutsch-\u00d6sterreichische Leitlinie zur medikament\u00f6sen Postexpositionsprophylaxe der HIV-Infektion \u2013 Update 2018 (AWMF-Register-Nr.: 055-004). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/055-004l_S2k_Medikamentoese-Postexpositionsprophylaxe-PEP-nach-HIV-Exposition_2018-12.pdf. Zugegriffen: 16. Sep. 2021"},{"key":"1233_CR3","unstructured":"Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF) (2018) Deutsch-\u00d6sterreichische Leitlinien zur HIV-Pr\u00e4expositionsprohphylaxe (PrEP) (AWMF-Register-Nr.: 055-008). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/055-008l_S2k_HIV-Praeexpositionsprophylaxe_2019-01_01.pdf. Zugegriffen: 16. Sep. 2021"},{"key":"1233_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah\u00a0T, Kowdley\u00a0KV, Zadeikis\u00a0N et\u00a0al (2018) Efficacy of Glecaprevir\/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol 16:417\u2013426","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1233_CR5","unstructured":"Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF) (2019) S2k-Leitlinie Virusinfektionen bei Organ- und allogen Stammzell-Transplantierten: Diag-nostik, Pr\u00e4vention und Therapie (AWMF Registernummer 093-002). https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/093-002l_S2k_Virusinfektionen-Organtransplantierte-alloge-Stammzell-Transplantierten-Diagnostik-Praevention-Therapie__2019-06.pdf. Zugegriffen: 15. Sep. 2021"},{"key":"1233_CR6","unstructured":"Arbeitsgemeinschaft Der Wissenschaftlichen Medizinischen Fachgesellschaften e.\u202fV. (AWMF) (2021) S3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virus-Infektion. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/021-011l_S3_Prophylaxe-Diagnostik-Therapie-der-Hepatitis-B-Virusinfektion_2021-07.pdf. Zugegriffen: 15. Sep. 2021"},{"key":"1233_CR7","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel\u00a0JH, Tomashek\u00a0KM, Dodd\u00a0LE et al (2020) Remdesivir for the treatment of Covid-19\u2014final report. N\u00a0Engl J Med 383:1813\u20131826","journal-title":"N Engl J Med"},{"key":"1233_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1090-3801(99)90015-0","volume":"3","author":"D Bowsher","year":"1999","unstructured":"Bowsher\u00a0D (1999) The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population. Eur J Pain 3:335\u2013342","journal-title":"Eur J Pain"},{"key":"1233_CR9","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.07.470392","author":"Y Cao","year":"2021","unstructured":"Cao\u00a0Y, Wang\u00a0J, Jian\u00a0F et\u00a0al (2021) B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes. bioRxiv. https:\/\/doi.org\/10.1101\/2021.12.07.470392","journal-title":"bioRxiv"},{"key":"1233_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jama.2021.8828","volume":"326","author":"MS Cohen","year":"2021","unstructured":"Cohen\u00a0MS, Nirula\u00a0A, Mulligan\u00a0MJ et al (2021) Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial. JAMA 326:46\u201355","journal-title":"JAMA"},{"key":"1233_CR11","volume-title":"Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion (AWMF-Register-Nr.: 055-001)","author":"Deutsche Aids Gesellschaft (DAIG)","year":"2020","unstructured":"Deutsche Aids Gesellschaft (DAIG) (2020) Deutsch-\u00d6sterreichische Leitlinien zur antiretroviralen Therapie der HIV-1-Infektion (AWMF-Register-Nr.: 055-001)"},{"key":"1233_CR12","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","volume":"385","author":"J Dobson","year":"2015","unstructured":"Dobson\u00a0J, Whitley\u00a0RJ, Pocock\u00a0S et al (2015) Oseltamivir treatment for influenza in adults: a\u00a0meta-analysis of randomised controlled trials. Lancet 385:1729\u20131737","journal-title":"Lancet"},{"key":"1233_CR13","first-page":"Doc02","volume":"9","author":"SC Duwe","year":"2021","unstructured":"Duwe\u00a0SC, Schmidt\u00a0B, G\u00e4rtner\u00a0BC et\u00a0al (2021) Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations. GMS Infect Dis 9:Doc2","journal-title":"GMS Infect. Dis."},{"key":"1233_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jmv.1890410503","volume":"1","author":"GB Elion","year":"1993","unstructured":"Elion\u00a0GB (1993) Acyclovir: discovery, mechanism of action, and selectivity. J\u00a0Med Virol Suppl 1:2\u20136","journal-title":"J Med Virol Suppl"},{"key":"1233_CR15","unstructured":"European Aids Clinical Society (EACS) (2020) EACS Guidelines 10.1. https:\/\/www.eacsociety.org\/media\/guidelines-10.1_30032021_1.pdf. Zugegriffen: 20. Sep. 2021"},{"key":"1233_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/irv.12216","volume":"8","author":"JE Fielding","year":"2014","unstructured":"Fielding\u00a0JE, Kelly\u00a0HA, Mercer\u00a0GN et\u00a0al (2014) Systematic review of influenza A(H1N1)pdm09 virus shedding: duration is affected by severity, but not age. Influenza Other Respir Viruses 8:142\u2013150","journal-title":"Influenza Other Respir Viruses"},{"key":"1233_CR17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","volume":"156","author":"AJ Gehring","year":"2019","unstructured":"Gehring\u00a0AJ, Protzer\u00a0U (2019) Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology 156:325\u2013337","journal-title":"Gastroenterology"},{"key":"1233_CR18","unstructured":"Gilead Sciences. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2021\/9\/veklury-remdesivir-significantly-reduced-risk-of-hospitalization-in-highrisk-patients-with-covid19. Zugegriffen: 14. Dez. 2021"},{"key":"1233_CR19","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.14.21267769","author":"H Gruell","year":"2021","unstructured":"Gruell\u00a0H, Vanshylla\u00a0K, Tober-Lau\u00a0P et\u00a0al (2021) mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. medRxiv. https:\/\/doi.org\/10.1101\/2021.12.14.21267769","journal-title":"medRxiv"},{"key":"1233_CR20","first-page":"571","volume":"25","author":"RE Hope-Simpson","year":"1975","unstructured":"Hope-Simpson\u00a0RE (1975) Postherpetic neuralgia. J\u00a0R Coll Gen Pract 25:571\u2013575","journal-title":"J R Coll Gen Pract"},{"key":"1233_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11908-019-0682-9","volume":"21","author":"P Ichai","year":"2019","unstructured":"Ichai\u00a0P, Samuel\u00a0D (2019) Management of Fulminant Hepatitis B. Curr Infect Dis Rep 21:25","journal-title":"Curr Infect Dis Rep"},{"key":"1233_CR22","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.10.21265889","volume-title":"Repeat Subcutaneous Administration of REGEN-COV\u00ae in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19","author":"F Isa","year":"2021","unstructured":"Isa\u00a0F, Forleo-Neto\u00a0E, Meyer\u00a0J et\u00a0al (2021) Repeat Subcutaneous Administration of REGEN-COV\u00ae in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19. https:\/\/doi.org\/10.1101\/2021.11.10.21265889"},{"key":"1233_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2471\/BLT.19.237149","volume":"98","author":"C James","year":"2020","unstructured":"James\u00a0C, Harfouche\u00a0M, Welton\u00a0NJ et\u00a0al (2020) Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull World Health Organ 98:315\u2013329","journal-title":"Bull World Health Organ"},{"key":"1233_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","author":"A Jayk Bernal","year":"2021","unstructured":"Jayk Bernal\u00a0A, Gomes da Silva\u00a0MM, Musungaie\u00a0DB, Kovalchuk\u00a0E, Gonzalez\u00a0A, Delos Reyes\u00a0V, Mart\u00edn-Quir\u00f3s\u00a0A, Caraco\u00a0Y, Williams-Diaz\u00a0A, Brown\u00a0ML, Du\u00a0J, Pedley\u00a0A, Assaid\u00a0C, Strizki\u00a0J, Grobler\u00a0JA, Shamsuddin\u00a0HH, Tipping\u00a0R, Wan\u00a0H, Paschke\u00a0A, Butterton\u00a0JR, Johnson\u00a0MG, De Anda\u00a0C (2021) Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine. https:\/\/doi.org\/10.1056\/NEJMoa2116044","journal-title":"New England Journal of Medicine"},{"key":"1233_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008965.pub4","author":"T Jefferson","year":"2014","unstructured":"Jefferson\u00a0T, Jones\u00a0MA, Doshi\u00a0P et\u00a0al (2014) Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD008965.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"47","key":"1233_CR26","first-page":"A-2212\/B-1825","volume":"118","author":"C Karagiannidis","year":"2021","unstructured":"Karagiannidis\u00a0C, Lang\u00a0K, Mikolajewska\u00a0A, Malin\u00a0JJ, Kluge\u00a0S, Spinner\u00a0CD (2021) Therapie und Prophylaxe: Antik\u00f6rper gegen COVID-19. Dtsch Arztebl 118(47):A-2212\/B-1825","journal-title":"Dtsch Arztebl"},{"key":"1233_CR27","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.m2021.0374","author":"S Kluge","year":"2021","unstructured":"Kluge\u00a0S, Malin\u00a0JJ, Fichtner\u00a0F, M\u00fcller\u00a0OJ, Skoetz\u00a0N, Karagiannidis\u00a0C (2021) Recommendations on the in-hospital treatment of patients with COVID-19. Deutsches \u00c4rzteblatt international. https:\/\/doi.org\/10.3238\/arztebl.m2021.0374","journal-title":"Deutsches \u00c4rzteblatt international"},{"key":"1233_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013825.pub2","author":"N Kreuzberger","year":"2021","unstructured":"Kreuzberger\u00a0N, Hirsch\u00a0C, Chai\u00a0KL, Tomlinson\u00a0E, Khosravi\u00a0Z, Popp\u00a0M, Neidhardt\u00a0M, Piechotta\u00a0V, Salomon\u00a0S, Valk\u00a0SJ, Monsef\u00a0I, Schmaderer\u00a0C, Wood\u00a0EM, So-Osman\u00a0C, Roberts\u00a0DJ, McQuilten\u00a0Z, Estcourt\u00a0LJ, Skoetz\u00a0N (2021) SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews. https:\/\/doi.org\/10.1002\/14651858.CD013825.pub2","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"1233_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00108-019-0564-0","volume":"60","author":"C Lehmann","year":"2019","unstructured":"Lehmann\u00a0C, Malin\u00a0J, Su\u00e1rez\u00a0I et\u00a0al (2019) Modern HIV treatment. Internist 60:411\u2013419","journal-title":"Internist"},{"key":"1233_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok\u00a0AS, Zoulim\u00a0F, Dusheiko\u00a0G et\u00a0al (2017) Hepatitis B cure: From discovery to regulatory approval. J\u00a0Hepatol 67:847\u2013861","journal-title":"J Hepatol"},{"key":"1233_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00162-20","author":"JJ Malin","year":"2020","unstructured":"Malin\u00a0JJ, Su\u00e1rez\u00a0I, Priesner\u00a0V et\u00a0al (2020) Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. https:\/\/doi.org\/10.1128\/cmr.00162-20","journal-title":"Clin Microbiol Rev"},{"key":"1233_CR32","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty\u00a0FM, Ljungman\u00a0P, Chemaly\u00a0RF et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433\u20132444","journal-title":"N. Engl. J. Med."},{"key":"1233_CR33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.282.5386.103","volume":"282","author":"AU Neumann","year":"1998","unstructured":"Neumann\u00a0AU, Lam\u00a0NP, Dahari\u00a0H et al (1998) Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon\u2011\u03b1 Therapy. Science 282:103\u2013107","journal-title":"Science"},{"key":"1233_CR34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109682","author":"MP O\u2019brien","year":"2021","unstructured":"O\u2019brien\u00a0MP, Forleo-Neto\u00a0E, Musser\u00a0BJ et\u00a0al (2021) Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2109682","journal-title":"N Engl J Med"},{"key":"1233_CR35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2023184","volume":"384","author":"H Pan","year":"2021","unstructured":"Pan\u00a0H, Peto\u00a0R, Henao-Restrepo\u00a0AM et al (2021) Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results. N Engl J Med 384:497\u2013511","journal-title":"N. Engl. J. Med."},{"key":"1233_CR36","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3350\/cmh.2016.0024","volume":"22","author":"V Pattullo","year":"2016","unstructured":"Pattullo\u00a0V (2016) Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol 22:219\u2013237","journal-title":"Clin. Mol. Hepatol."},{"key":"1233_CR37","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2016.0274","author":"M Ringelhan","year":"2017","unstructured":"Ringelhan\u00a0M, McKeating\u00a0JA, Protzer\u00a0U (2017) Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. https:\/\/doi.org\/10.1098\/rstb.2016.0274","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"1233_CR38","doi-asserted-by":"publisher","first-page":"e13105","DOI":"10.15252\/emmm.202013105","volume":"13","author":"A Simonis","year":"2021","unstructured":"Simonis\u00a0A, Theobald\u00a0SJ, F\u00e4tkenheuer\u00a0G et al (2021) A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV\u20112. EMBO Mol Med 13:e13105","journal-title":"EMBO Mol Med"},{"key":"1233_CR39","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","volume":"324","author":"CD Spinner","year":"2020","unstructured":"Spinner\u00a0CD, Gottlieb\u00a0RL, Criner\u00a0GJ et al (2020) Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA 324:1048\u20131057","journal-title":"JAMA"},{"key":"1233_CR40","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1080\/03007995.2019.1584505","volume":"35","author":"V Taieb","year":"2019","unstructured":"Taieb\u00a0V, Ikeoka\u00a0H, Ma\u00a0FF et al (2019) A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin 35:1355\u20131364","journal-title":"Curr Med Res Opin"},{"key":"1233_CR41","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research (2021) FDA Briefing Document Antimicrobial Drugs Advisory Committee Meeting November 30, 2021. Verf\u00fcgbar unter: https:\/\/www.fda.gov\/media\/154418\/download. Zugegriffen: 16. Dez. 2021"},{"key":"1233_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1708","author":"F Van B\u00f6mmel","year":"2021","unstructured":"Van B\u00f6mmel\u00a0F, Berg\u00a0T (2021) Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A\u00a0Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis\u00a0B. Hepatol Commun. https:\/\/doi.org\/10.1002\/hep4.1708","journal-title":"Hepatol Commun"},{"issue":"23","key":"1233_CR43","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich\u00a0DM, Sivapalasingam\u00a0S, Norton\u00a0T, Ali\u00a0S, Gao\u00a0H, Bhore\u00a0R, Xiao\u00a0J, Hooper\u00a0AT, Hamilton\u00a0JD, Musser\u00a0BJ, Rofail\u00a0D, Hussein\u00a0M, Im\u00a0J, Atmodjo\u00a0DJ, Perry\u00a0C, Pan\u00a0C, Mahmood\u00a0A, Hosain\u00a0R, Davis\u00a0JD, Turner\u00a0KC, Baum\u00a0A, Kyratsous\u00a0CA, Kim\u00a0Y, Cook\u00a0A, Kampman\u00a0W, Roque-Guerrero\u00a0L, Acloque\u00a0G, Aazami\u00a0H, Cannon\u00a0K, Sim\u00f3n-Campos\u00a0JA, Bocchini\u00a0JA, Kowal\u00a0B, DiCioccio\u00a0AT, Soo\u00a0Y, Geba\u00a0GP, Stahl\u00a0N, Lipsich\u00a0L, Braunstein\u00a0N, Herman\u00a0G, Yancopoulos\u00a0GD (2021) REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. New England Journal of Medicine 385(23):e81. https:\/\/doi.org\/10.1056\/NEJMoa2108163","journal-title":"New England Journal of Medicine"},{"key":"1233_CR44","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang\u00a0Y, Zhang\u00a0D, Du\u00a0G et al (2020) Remdesivir in adults with severe COVID-19: a\u00a0randomised, double-blind, placebo-controlled, multicentre trial. Lancet 395:1569\u20131578","journal-title":"Lancet"},{"key":"1233_CR45","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.2169\/internalmedicine.4117-19","volume":"59","author":"N Yoshii","year":"2020","unstructured":"Yoshii\u00a0N, Tochino\u00a0Y, Fujioka\u00a0M et\u00a0al (2020) The Comparison of the Efficacy of Baloxavir and Neuraminidase Inhibitors for Patients with Influenza A in Clinical Practice. Intern Med 59:1509\u20131513","journal-title":"Intern Med"},{"key":"1233_CR46","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","volume":"18","author":"E Zuckerman","year":"2020","unstructured":"Zuckerman\u00a0E, Gutierrez\u00a0JA, Dylla\u00a0DE et al (2020) Eight Weeks of Treatment With Glecaprevir\/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Na\u00efve Patients With Hepatitis C Virus Infection. Clin Gastroenterol Hepatol 18:2544\u20132553.e6","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01233-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01233-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T11:03:53Z","timestamp":1642158233000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01233-4"}},"subtitle":["Potente Wirkstoffe, Hoffnungstr\u00e4ger bei COVID\u201119 und therapeutische Grenzen"],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01233-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.J.\u00a0Malin erhielt Beraterhonorare von MAPLE Health Group und Atriva Therapeutics GmbH, Reisekostenerstattungen von Gilead Sciences, ViiV Healthcare und Correvio Pharma sowie institutionelle Forschungsgelder vom Deutschen Zentrum f\u00fcr Infektionsforschung (DZIF) und den U.S.\u00a0National Institutes of Health (NIH). Christoph Spinner erkl\u00e4rt, Reisekosten- und Kongressunterst\u00fctzung der Firmen AbbVie, Astellas, Bristol-Meyers Squibb, Gilead Sciences, Janssen-Cilag, Pfizer und ViiV Healthcare erhalten zu haben. Der Autor ist oder war beratend f\u00fcr AbbVie, Apeiron, B.\u00a0Braun Melsungen, Cepheid, Formycon, Gilead Sciences, GSK, Janssen-Cilag, Merck Sharp & Dome, Molecular Partners und ViiV Healthcare t\u00e4tig. Der Autor ist oder war an multizentrischen Studien der Firmen AbbVie, Apeiron, B.\u00a0Braun Melsungen, Gilead Sciences, Janssen-Cilag, Sanofi Aventis und ViiV Healthcare beteiligt. Dar\u00fcber hinaus bestehen oder bestanden Drittmittelzuwendungen f\u00fcr Forschungsprojekte durch die Firmen Gilead Sciences, Janssen-Cilag, ViiV Healthcare sowie das nationale Netzwerk Universit\u00e4tsmedizin, Berlin, und das Deutsche Zentrum f\u00fcr Infektionsforschung (DZIF), Braunschweig. Ulrike Protzer ist bzw. war in den letzten 5\u00a0Jahren beratend f\u00fcr die Firmen AbbVie, Arbutus, BioNTech, Gilead, GSK, Johnson & Johnson, Pfizer, Roche, Sanofi, Sobi und Vaccitech t\u00e4tig. Sie ist Mitgr\u00fcnderin und Anteilsinhaberin von SCG Cell Therapy. Ulrike Protzer erh\u00e4lt Forschungsunterst\u00fctzung von ALiOS and Vir Biotechnology. Zudem werden die Projekte ihres Labors von der Deutschen Forschungsgemeinschaft (DFG), dem NIH, dem DZIF, dem Bundesministerium f\u00fcr Bildung und Forschung (BMBF), dem nationalen Netzwerk Universit\u00e4tsmedizin, der EU im Rahmen des Horizon-2020-Programms, dem Bayerischen Staatsministerium f\u00fcr Wissenschaft und Kunst im Rahmen der Konsortien FOR-Covid und CoVaKo, der Helmholtz Gemeinschaft sowie der Bayerischen Forschungsstiftung gef\u00f6rdert. T.\u00a0Bunse gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}